FEN1 Inhibition as a Potential Novel Targeted Therapy against Breast Cancer and the Prognostic Relevance of FEN1
To enhance cancer of the breast treatment and also to enable new techniques for therapeutic resistance, therapeutic targets are continually being studied. Potential targets are proteins of DNA repair and replication and genomic integrity, for example Flap Endonuclease 1 (FEN1). This research investigated the results of FEN1 inhibitor FEN1-IN-4 in conjunction with ionizing radiation on cell dying, clonogenic survival, the cell cycle, senescence, doubling time, DNA double-strand breaks and micronuclei in cancer of the breast cells, breast cells and healthy skin fibroblasts. In addition, the variation within the baseline FEN1 level and it is affect on treatment prognosis was investigated. The cell lines show specific response patterns within the aspects studied and also have heterogeneous baseline FEN1 levels. FEN1-IN-4 has cytotoxic, cytostatic and radiosensitizing effects, expressed through growing cell dying by apoptosis and necrosis, G2M share, senescence, double-strand breaks along with a reduced survival fraction. Nonetheless, some cells are less impacted by the cytotoxicity and fibroblasts show an extremely limited response. In vivo, high FEN1 mRNA expression worsens the prognosis of cancer of the breast patients. Because of the elevated expression in cancer of the breast tissue, FEN1 could represent a brand new tumor and prognosis marker and FEN1-IN-4 is a brand new potent agent in personalized medicine and targeted cancer of the breast therapy.